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Abstract Glucose-6-phosphate dehydrogenase (G6PD) deficiency is believed to confer
protection against Plasmodium falciparum malaria, but the precise nature of the protective effect
has proved difficult to define as G6PD deficiency has multiple allelic variants with different effects
in males and females, and it has heterogeneous effects on the clinical outcome of P. falciparum
infection. Here we report an analysis of multiple allelic forms of G6PD deficiency in a large multi-
centre case-control study of severe malaria, using the WHO classification of G6PD mutations to
estimate each individual’s level of enzyme activity from their genotype. Aggregated across all
genotypes, we find that increasing levels of G6PD deficiency are associated with decreasing risk of
cerebral malaria, but with increased risk of severe malarial anaemia. Models of balancing selection
based on these findings indicate that an evolutionary trade-off between different clinical outcomes
of P. falciparum infection could have been a major cause of the high levels of G6PD polymorphism
seen in human populations.
DOI: 10.7554/eLife.15085.001
Introduction
Glucose-6-phosphate dehydrogenase (G6PD), encoded by the G6PD gene on chromosome X, is an
enzyme that acts to control oxidative damage in red blood cells. G6PD deficiency is a common
human genetic condition with many allelic variants causing different levels of enzyme deficiency, so
that in some individuals it is asymptomatic whereas in others it can cause severe haemolytic anaemia
(Beutler, 1994; Beutler and Vulliamy, 2002; Beutler, 2008; Minucci et al., 2012). The geographi-
cal distribution of G6PD deficiency corresponds to regions of the world where malaria is endemic, or
has been in the relatively recent past, and it has been estimated that approximately 350 million peo-
ple living in malaria-endemic countries are affected (Allison, 1960; Motulsky, 1960; Howes et al.,
2012).
It was proposed over half a century ago, and is now widely accepted, that G6PD deficiency has
risen to high frequency in malaria-endemic regions because it confers some level of resistance to
malaria (Allison, 1960; Luzzatto, 2015). Evolutionary support for this hypothesis is provided by hap-
lotype and sequence analyses indicating that G6PD variants have evolved independently, at a fre-
quency that is inconsistent with random genetic drift, and over a period of time that is consistent
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with the estimated time since the emergence of malaria (Tishkoff et al., 2001; Sabeti et al., 2002;
Saunders et al., 2002; Verrelli et al., 2002; Saunders et al., 2005).
Although there is a large body of circumstantial evidence to suggest that G6PD deficiency con-
fers resistance to malaria, there has been much debate about the precise nature of the protective
effect. This is partly due to the genetic complexity of the locus, being X-linked with multiple defi-
ciency alleles with the result that it has extensive allelic and phenotypic heterogeneity, and also to
the fact that clinical and epidemiological studies have appeared to give conflicting results. An early
study concluded that G6PD deficiency protects against P. falciparum malaria in heterozygous
females (Bienzle et al., 1972) and this is supported by a number of more recent studies
(Manjurano et al., 2012; Sirugo et al., 2014; Luzzatto, 2015; Manjurano et al., 2015;
Uyoga et al., 2015). However other studies have indicated that the protective effect is present in
both heterozygous females and hemizygous males (Ruwende et al., 1995; Clark et al., 2009;
Shah et al., 2016) or that it is confined to hemizygous G6PD-deficient males (Guindo et al., 2007),
or that there are no protective effects at all (Johnson et al., 2009; Toure et al., 2012).
The question of whether G6PD deficiency confers resistance to severe malaria, i.e. to life-threat-
ening complications of P. falciparum infection, was recently examined in a multi-centre case-control
study of much larger sample size than previous studies (Malaria Genomic Epidemiology Network,
2014). Standardised clinical definitions were used to categorise cases of severe malaria into sub-
phenotypes, the main ones being cerebral malaria and severe malarial anaemia. It was found that
both female heterozygotes and male hemizygotes for the main African form of G6PD deficiency
(encoded by the derived allele of rs1050828 (G6PD c.202C>T)) had reduced risk of cerebral malaria,
but this benefit was offset by increased risk of severe malarial anaemia in male hemizygotes and
female homozygotes. By contrast, the sickle cell trait and blood group O were very strongly associ-
ated with reduced risk of both cerebral malaria and severe malarial anaemia in the same samples.
(Malaria Genomic Epidemiology Network, 2014, 2015). G6PD deficiency thus appears to have a
more complex mode of action than other malaria-resistance factors, reducing the risk of some life-
threatening complications of P. falciparum infection, but increasing the risk of others.
The present study had two main aims. The first aim was to perform a more comprehensive analy-
sis of how an individual’s level of G6PD deficiency affects the risk of severe malaria in general, and
of cerebral malaria and severe malarial anaemia in particular. Previously published data are restricted
to specific G6PD-deficient alleles, and do not consider the great allelic heterogeneity of this locus,
or the fact that some allelic variants cause much more severe loss of G6PD enzyme function than
others (Beutler and Vulliamy, 2002; Minucci et al., 2012). We therefore surveyed a broad range of
G6PD-deficient alleles, using the World Health Organisation (WHO) system that classifies known alle-
lic variants into different levels of severity according to the amount of enzyme function that is lost
(Yoshida et al., 1971). The second aim of the study was to explore evolutionary and epidemiological
models that are based on these new findings to re-examine the hypothesis that P. falciparum malaria
is a major force for balancing selection of G6PD.
Results
Study population
Individuals with severe P. falciparum malaria and population controls were recruited in Burkina Faso,
Cameroon, The Gambia, Ghana, Kenya, Malawi, Mali, Nigeria, Tanzania, Vietnam and Papua New
Guinea as described elsewhere (Malaria Genomic Epidemiology Network, 2008, 2014). After data
curation and quality control, this analysis included 11,871 cases of severe malaria and 16,889 popula-
tion controls. (Table 1, Supplementary files 1A,B). A total of 3,359 individuals had cerebral malaria
only, 2,184 had severe malarial anaemia only, 741 had both cerebral malaria and severe malarial
anaemia, and 5,587 cases fulfilled other WHO criteria for severe malaria (World Health Organisa-
tion, 2000). All of the severe malaria cases recruited in Africa were children: the median age of
those with severe malarial anaemia was 1.8 years (interquartile range [IQR] 1.0–3.0) and that of
those with cerebral malaria, 3.4 years (2.1–5.8). These differences in age, and variations in clinical
patterns of disease at different geographical locations, were consistent with previous reports
(Slutsker et al., 1994; Snow et al., 1994, 1997; Modiano et al., 1998; Newton and Krishna, 1998;
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Marsh and Snow, 1999; Pasvol, 2005; Reyburn et al., 2005; Idro et al., 2006; Okiro et al., 2009;
Thuma et al., 2011). The overall case fatality rate was 10%.
Survey of G6PD variation in the study population
We identified a set of 70 single nucleotide polymorphisms (SNPs) of functional or genetic relevance
in a 560 kb region spanning the G6PD locus and part of the overlapping IKBKG gene (encoding
Inhibitor of Kappa Light Polypeptide Gene Enhancer in B-Cells) (see Materials and methods). Of
these, five SNPs failed quality control and six were monomorphic (Supplementary file 1C). The
remaining 59 SNPs showed variation in allele frequency between study sites, with a median FST of
0.024 (range 0 to 0.67). Fifteen SNPs expressed phenotypically deficient G6PD activity according to
the WHO classification system (Beutler and Vulliamy, 2002; Minucci et al., 2012) , in which class I
represents the most severe deficiency mutation and class IV the least (Table 2). The most common
deficiency haplotype in sub-Saharan Africa, often referred to as G6PD A–, is composed of derived
alleles at class III variant rs1050828 (G6PD c.202C>T, here referred to as G6PD+202) and class IV
variant rs1050829 (G6PD c.376T>C, here referred to as G6PD+376). These two alleles, here referred
to as G6PD+202T and G6PD+376C, were observed at all of the African study sites in strong linkage
disequilibrium, with average allele frequencies of 15% and 39%, respectively, but neither was pres-
ent in Papua New Guinea or Vietnam. Four other deficiency alleles were observed at >1% frequency
in specific populations: the class III variant rs76723693 (G6PD c.968T>C) and the class II variant
rs5030872 (G6PD c.542A>T) had deficiency allele frequencies of 7% and 1.5%, respectively, in The
Gambia; and the class II variants rs137852327 and rs78365220 had deficiency allele frequencies of
1.4% and 3.7%, respectively, in Papua New Guinea. All of other G6PD deficiency alleles observed in
this study were at <1% frequency in all populations. The only class I deficiency allele was at
CM973154, where it was present in just three Gambian individuals.
Analysis of association with individual variants
As reported previously (Malaria Genomic Epidemiology Network, 2014), G6PD+202T was associ-
ated with an increased risk of severe malarial anaemia (odds ratio [OR] = 1.18, p = 7.5x10 5) and a
Table 1. Clinical phenotype case counts, percentage of fatalities and descriptive statistics. Numbers are given for cases and controls
of all severe malaria by study site, with the percentage of case fatalities shown in parentheses. Cases are further divided into those
with cerebral malaria, severe malarial anaemia, both cerebral malaria and severe malarial anaemia, and other severe malaria. Percent-
age of males refers to cases and controls. CM, cerebral malaria; SMA, severe malarial anaemia.
Study site Case and control counts (% fatality) % males Age in years (IQR)
CM SMA
CM and
SMA
Other
severe
malaria Total cases
Total
controls CM SMA
All severe
malaria Controls*
Gambia 815 (26) 470 (5) 139 (24) 1,082 (7) 2,506 (14) 3,281 51.2 4.5 (3–7) 2.3 (1.5–3.9) 3.8 (2.2–5.9) 0
Mali 78 (27) 182 (8) 69 (22) 107 (12) 436 (15) 328 53.3 5 (3.5–7.2) 2 (1.2–3.4) 3 (1.7–5) 3 (2–5)
Burkina Faso 107 (20) 38 (11) 20 (20) 681 (1) 846 (5) 721 54.0 4 (3–6) 2.8 (2–4) 3.8 (2–6) 3 (2–4)
Ghana (Navrongo) 21 (24) 244 (2) 14 (36) 389 (3) 668 (4) 197 56.7 1.8 (1.1–2.4) 1.1 (0.8–1.8) 1.3 (0.9–2) 1.2 (0.8–1.7)
Ghana (Kumasi) 230 (10) 548 (2) 76 (13) 635 (2) 1,489 (4) 2,027 52.2 2.5 (1.5–4) 1.3 (0.8–2.5) 2 (1–3.7) 0
Nigeria 6 (17) 7 (14) 0 (0) 64 (2) 77 (4) 40 57.0 1.7 (1–5.6) 2.2 (1.6–4.5) 3 (1.6–4) 2.6 (1.1–3.9)
Cameroon 39 (18) 82 (7) 8 (50) 493 (2) 622 (5) 576 60.7 3 (1.4–4.2) 2 (1.2–3.5) 2.1 (1.2–4) 21 (7.5–28)
Kenya 901 (13) 158 (8) 213 (16) 972 (8) 2,244 (11) 3,935 50.9 2.6 (1.6–3.8) 1.8 (1–3) 2.2 (1.2–3.6) 0.5 (0.4–0.7)
Tanzania 34 (41) 179 (4) 28 (29) 186 (11) 427 (11) 455 49.0 2.3 (1.7–3.8) 1.5 (0.9–2.5) 1.7 (1.1–2.7) 2.9 (2.1–3.9)
Malawi 875 (15) 129 (7) 157 (20) 219 (27) 1380 (17) 2,582 52.0 3 (2–4.7) 2.2 (1.1–3.1) 2.8 (1.8–4.2) 0
Vietnam 209 (18) 31 (6) 8 (12) 545 (9) 793 (11) 2,505 58.6 30 (22–42) 24 (17.5–37.5) 29 (22–41) 0
Papua New Guinea 44 (5) 116 (2) 9 (11) 214 (1) 383 (2) 242 55.3 3.8 (2.6–5) 2.2 (1.3–3.2) 2.9 (2.1–4.3) 3.3 (2.2–4.8)
Total 3,359 (18) 2,184 (5) 741 (20) 5,587 (6) 11,871 (10) 16,889 53.1 3.4 (2.1–5.8) 1.8 (1–3) 2.8 (1.5–5) 0 (0–0.7)
*Four sites used cord blood controls (i.e. age 0).
DOI: 10.7554/eLife.15085.002
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decreased risk of cerebral malaria (OR = 0.91, p = 7.2x10 3) in males and females combined under
an additive genetic model (Table 3 and Supplementary files 1D–F). Increased risk of severe malarial
anaemia was observed in male hemizygotes (OR = 1.48, p = 6.6x10 5) and female homozygotes
(OR = 1.86, p = 3.4x10 3); and there was a trend for decreased risk of cerebral malaria in male hemi-
zygotes (OR = 0.82, p = 0.02) and female heterozygotes (OR = 0.87, p = 0.05).
To investigate other SNPs, we began by testing individual variants for association with severe
malaria, cerebral malaria and severe malarial anaemia across all study populations. This analysis
assumed fixed effects across populations, under a variety of modes of inheritance, for males and
females separately (see Materials and methods). Six variants other than G6PD+202 showed evidence
of association with severe malarial anaemia (p<1x10 3) but they were all in linkage disequilibrium
with G6PD+202 and these associations disappeared after adjusting for the known effects of G6PD
+202 (Figure 1, Table 4). In these analyses, we corrected for the effects of the sickle-cell trait
because of its strong protective effect against both cerebral malaria and severe malarial anaemia.
We also examined the HbC variant, and the ABO, ATP2B4, and FREM3/GYPE loci, which have well-
validated protective effects against severe malaria (Malaria Genomic Epidemiology Network,
2014, 2015) and found no evidence that they affected the association of G6PD variants with severe
malaria (Figure 1—figure supplement 3). The available data did not allow us to analyse a thalasse-
mia across all study sites, but recent analyses at individual study sites have shown no evidence of
interaction between the malaria-protective effects of G6PD deficiency and a thalassemia
(Manjurano et al., 2015; Uyoga et al., 2015).
The above analyses assume that variants have the same effects in different locations, but variation
in patterns of disease association can arise due to a range of genetic, biological and environmental
factors. We therefore evaluated different models of genetic association allowing for heterogeneity
of effect at different locations and on different sub-phenotypes (Materials and methods; Figure 1—
figure supplement 1). As expected G6PD+202T showed strong evidence of heterogeneity of effect
on different sub-phenotypes, with more than 90% of the posterior weight resting on models indicat-
ing different effects on cerebral malaria and severe malarial anaemia. Evidence for heterogeneity of
effect was also seen at rs73573478, which showed variation of effect at different locations rather
Table 2. WHO-classified G6PD deficiency alleles observed in this study. Locus refers to GRCh37, dbSNP137 and Ensembl build 84.
WHO refers to grade of G6PD deficiency based on the WHO classification scheme. Allele frequency is calculated in population con-
trols. GM Gambia; ML, Mali; BF, Burkina Faso; GH-N, Ghana (Noguchi); GH-K, Ghana (Kumasi); NG Nigeria; CM, Cameroon; KY,
Kenya; TZ, Tanzania; MW, Malawi; VN, Vietnam; PNG, Papua New Guinea.
SNP Locus Base change WHO
Allele frequency
GM ML BF GH-N GH-K NG CM KY TZ MW VN PNG
CM973154 153760261 A/C I 0.0004 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
rs72554665 153760484 C/A II 0.0004 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0055 0.0000
CM920290 153760605 G/A II 0.0002 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0014 0.0028
rs137852342 153761184 G/A III 0.0000 0.0020 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0014 0.0000
rs76723693 153761240 968T>C III 0.0695 0.0082 0.0009 0.0000 0.0003 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
rs137852327 153761337 C/T II 0.0006 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0096 0.0141
CM014189 153761820 T/A II 0.0004 0.0000 0.0000 0.0000 0.0008 0.0000 0.0000 0.0004 0.0000 0.0000 0.0000 0.0000
rs137852328 153762340 680G>T III 0.0002 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
rs137852330 153762605 G/A II 0.0004 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0003 0.0000
rs5030868 153762634 563G>A II 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0003 0.0000 0.0000 0.0000 0.0085
rs5030872 153762655 542A>T II 0.0145 0.0041 0.0009 0.0000 0.0003 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
CM970547 153763462 G/A II 0.0008 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
rs78365220 153763485 A/G II 0.0002 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0366
rs1050829 153763492 376T>C IV 0.3206 0.4132 0.4186 0.4476 0.4267 0.5574 0.3429 0.4060 0.3787 0.3920 0.0000 0.0000
rs1050828 153764217 202C>T III 0.0273 0.1616 0.1447 0.1713 0.1847 0.3167 0.1075 0.1930 0.2071 0.1988 0.0000 0.0000
DOI: 10.7554/eLife.15085.003
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than on different sub-phenotypes. For reasons of sample size, we did not conduct a detailed analysis
of sub-types of severe malaria other than cerebral malaria and severe malaria, but summary statistics
are available in Figure 1—source data 1 and 2.
In this dataset, the median age of those with severe malarial anaemia was 1.8 years and that of
those with cerebral malaria was 3.4 years (Table 1). This is consistent with previous studies of severe
malaria in African children, which have established that severe malarial anaemia tends to occur at a
younger age than cerebral malaria (Newton and Krishna, 1998; Taylor et al., 2006). We therefore
investigated the possible effect of age on associations with G6PD deficiency, dividing cases of
severe malaria into those occurring within two main groups of age <2 years or 2–6 years. In both
age groups, assuming an additive genetic model, the G6PD+202T allele was associated with
reduced risk of cerebral malaria (<2 years, OR = 0.93, 95% CI = 0.82–1.05; 2–6 years, OR = 0.88,
95% CI = 0.81–0.96) and increased risk of severe malarial anaemia (<2 years, OR = 1.16, 95% CI
= 1.05–1.28; 2–6 years, OR = 1.20, 95% CI = 1.06–1.36). We conclude from these findings, and from
Table 3. G6PD+202 best model association test results. p values and odds ratios, with 95% confidence interval, for association at
G6PD+202 with all cases of severe malaria and with the two sub-types cerebral malaria and severe malarial anaemia, for all samples
combined and separately for males and females. Results are shown for all sites combined and are adjusted for sickle-cell trait, ethnicity
and sex.
Sample Case phenotype Case frequency* Control frequency* Model† Model OR (95% CI) P Sites excluded‡
All Cerebral malaria 0.13 (2,528/337/231) 0.15 (11,155/1,701/1,229) A 0.91 (0.85–0.97) 7.2210 3 VN, PNG
0.13 (2,528/337/231) 0.15 (11,155/1,701/1,229) D 0.86 (0.77–0.95) 4.5410 3 VN, PNG
0.13 (2,528/337/231) 0.15 (11,155/1,701/1,229) R 0.86 (0.74–1) 0.06 VN, PNG
Severe malarial anaemia 0.17 (1,566/212/256) 0.15 (11,155/1,701/1,229) A 1.18 (1.09–1.28) 7.4810 5 VN, PNG
0.17 (1,566/212/256) 0.15 (11,155/1,701/1,229) D 1.21 (1.06–1.38) 5.4410 3 VN, PNG
0.17 (1,566/212/256) 0.15 (11,155/1,701/1,229) R 1.53 (1.29–1.82) 1.1910 6 VN, PNG
Severe malaria 0.14 (8,536/1,138/986) 0.15 (11,155/1,701/1,229) A 1.01 (0.97–1.06) 0.65 VN, PNG
0.14 (8,536/1,138/986) 0.15 (11,155/1,701/1,229) D 0.98 (0.92–1.05) 0.58 VN, PNG
0.14 (8,536/1,138/986) 0.15 (11,155/1,701/1,229) R 1.09 (0.99–1.2) 0.08 VN, PNG
Females Cerebral malaria 0.14 (1,145/337/38) 0.15 (4,933/1,701/168) A 0.91 (0.81–1.03) 0.15 VN, PNG
0.14 (1,145/337/38) 0.15 (4,933/1,701/168) D 0.88 (0.77–1.01) 0.08 VN, PNG
0.14 (1,145/337/38) 0.15 (4,933/1,701/168) H 0.87 (0.75–1) 0.05 VN, PNG
0.14 (1,145/337/38) 0.15 (4,933/1,701/168) R 1.06 (0.73–1.54) 0.75 VN, PNG
Severe malarial anaemia 0.16 (673/212/40) 0.15 (4,933/1,701/168) A 1.11 (0.95–1.29) 0.19 VN, PNG
0.16 (673/212/40) 0.15 (4,933/1,701/168) D 1.04 (0.87–1.24) 0.68 VN, PNG
0.16 (673/212/40) 0.15 (4,933/1,701/168) H 0.93 (0.77–1.13) 0.47 VN, PNG
0.16 (673/212/40) 0.15 (4,933/1,701/168) R 1.86 (1.23–2.81) 3.4010 3 VN, PNG
Severe malaria 0.14 (3,729/1,138/132) 0.15 (4,933/1,701/168) A 0.95 (0.88–1.03) 0.21 VN, PNG
0.14 (3,729/1,138/132) 0.15 (4,933/1,701/168) D 0.92 (0.84–1.01) 0.07 VN, PNG
0.14 (3,729/1,138/132) 0.15 (4,933/1,701/168) H 0.9 (0.82–0.99) 0.03 VN, PNG
0.14 (3,729/1,138/132) 0.15 (4,933/1,701/168) R 1.13 (0.88–1.45) 0.33 VN, PNG
Males Cerebral malaria 0.12 (1,379/–/193) 0.15 (6,207/–/1,058) M 0.82 (0.69–0.98) 0.03 NG, VN, PNG
Severe malarial anaemia 0.19 (893/–/216) 0.15 (6,222/–/1,061) M 1.48 (1.22–1.8) 6.5810 5 VN, PNG
Severe malaria 0.15 (4,807/–/854) 0.15 (6,222/–/1,061) M 1.08 (0.97–1.2) 0.14 VN, PNG
*Derived allele frequency and counts of wild-type homozygotes, heterozygotes and derived homozygotes, where male hemizygotes are counted as
female homozygotes.
†Models are additive (A), dominant (D), recessive (R) heterozygous model (H) or male hemizygous (M).
‡Sites at which an SNP is monomorphic in either cases or controls are excluded from the combined analysis. NG, Nigeria; VN, Vietnam; PNG, Papua
New Guinea.
DOI: 10.7554/eLife.15085.004
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Figure 1. Summary of single SNP tests of association at all sites combined. (A) Schematic of genes across the
genotyped region plotted relative to evenly spaced positions of SNPs in (B). (B) Manhattan plot showing
the results of all single SNP tests of association with all severe malaria and with cerebral malaria and severe
malarial anaemia for males, females and all individuals combined for models of association with additive,
dominant, recessive and heterozygous (females only) modes of inheritance. Mode of inheritance is indicated as
additive (A), dominant (D), recessive (R) or heterozygous (H) only for SNPs with a P value <110 3, as indicated by
the horizontal dashed grey line. See Figure 1—source data 1 for detailed association results. (C) As for (B), but
results are adjusted for additive effects at G6PD+202. See Figure 1—source data 2 for detailed association
Figure 1 continued on next page
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more detailed estimates of age-specific effects shown in Figure 1—figure supplement 2, that the
effects of G6PD on the risk of cerebral malaria and severe malarial anaemia are not significantly
affected by age.
Analysis of association with G6PD-deficiency score
Most of the G6PD-deficiency variants identified in this study occur at low frequency or are restricted
to specific populations, so we have relatively low statistical power to detect association with individ-
ual variants other than G6PD+202 and G6PD+376. One way of overcoming this problem is to amal-
gamate the evidence across multiple variants by considering their phenotypic effects. Although we
do not have information on the precise phenotypic effects of each of the variants observed in this
study, we can make an approximate estimate of an individual’s level of G6PD deficiency based on
their genotypes, using the WHO classification of functional severity of known mutations (Table 2).
All of the cases and controls were assigned a G6PD deficiency score (G6PDd score), defined as the
estimated level of G6PD deficiency for that individual, ranging from 0% (no loss of function) to 100%
(total loss of function), and calculated using the scoring system shown in Table 5 (see Materials and
methods).
The mean G6PDd score was 13.5% in controls, 13% in cerebral malaria cases and 16.9% in severe
malarial anaemia cases (Supplementary file 1J). If individuals carrying G6PD+202T are excluded,
the mean G6PDd score was 6% in controls, 5.6% in cerebral malaria cases and 7.1% in severe malar-
ial anaemia cases. This pattern of a higher mean G6PDd score in severe malarial anaemia cases com-
pared to that in controls and cerebral malaria cases was observed in both males and females and at
all sites other than Nigeria, Tanzania and Papua New Guinea (Supplementary file 1J). The most
severe G6PDd score observed was 95%: this was found in 95 individuals, mainly from The Gambia,
Vietnam and Papua New Guinea, who were homozygous for a class II mutation
(Supplementary files 1G–I).
We divided the G6PDd score into five categories: normal (G6PDd score = 0); low (0 < G6PDd
score < 25); medium (25  G6PDd score < 50); high (50  G6PDd score < 85); and very high
(G6PDd score  85). (Table 5 and Materials and methods.) In this system, the majority of G6PD
+202T heterozygotes were categorized as medium and all G6PD+202T homozygotes, including
male hemizygotes, were categorized as high. Only individuals carrying less severe WHO class IV
mutations were categorized as low and only individuals homozygous for more severe WHO class II
mutations had a very high G6PDd score. There were 16,236 individuals in the normal category,
6,633 in low, 3,311 in medium, 2,485 in high, and 95 with very high G6PDd score. No significant
Figure 1 continued
results with adjustment for G6PD+202. (D) Pairwise r2 between pairs of SNPs in control individuals. Samples are
excluded from analysis at sites where an SNP is monomorphic; this accounts for a variation in sample size across
SNPs. Results for SNPs that are monomorphic or extremely rare across all sites (maximum minor allele
frequency <0.01) are not shown. All results are adjusted for gender, ethnicity and the sickle-cell trait. See
Figure 1—figure supplement 1 for detailed forest plots of association at G6PD+202. See Figure 1—figure
supplement 2 for a summary of genetic heterogeneity of cerebral malaria and severe malarial anaemia within and
across African sites.
DOI: 10.7554/eLife.15085.005
The following source data and figure supplements are available for figure 1:
Source data 1. Single SNP association test results.
DOI: 10.7554/eLife.15085.006
Source data 2. Single SNP association test results with adjustment for additive effect of G6PD+202.
DOI: 10.7554/eLife.15085.007
Figure supplement 1. Genetic heterogeneity of severe malaria sub-phenotypes within and across African sites.
DOI: 10.7554/eLife.15085.008
Figure supplement 2. Association between G6PD deficiency and severe malaria sub-phenotypes stratified by
age.
DOI: 10.7554/eLife.15085.009
Figure supplement 3. Association between G6PD deficiency and severe malaria with and without adjustment for
additional genetic factors.
DOI: 10.7554/eLife.15085.010
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effects on cerebral malaria or severe malarial anaemia were observed at low G6PDd score. Individu-
als with medium G6PDd score had significant protection against cerebral malaria (OR = 0.86,
p = 0.04). Individuals with high G6PDd score had a stronger level of protection against cerebral
malaria (OR 0.8, p = 3.0x10 3) and an increased risk of severe malarial anaemia (OR = 1.49,
p = 2.2x10 6). Individuals with very high G6PDd score showed the strongest level of protection
against cerebral malaria (OR = 0.28, p = 0.03) and an increased risk of severe malarial anaemia
(OR = 1.44, p = 0.36), although the latter was not significant due to the smaller sample numbers
(Table 6 and Figure 2).
We can simplify the above findings by assuming a linear relationship between the log odds of dis-
ease and the G6PDd score. In this statistical model, each 10% increase in the G6PDd score
decreased the risk of cerebral malaria by approximately 4% (OR = 0.96, p = 5.6x10 5) and increased
the risk of severe malarial anaemia by approximately 5% (OR = 1.05, p = 1.4x10 4)
(Supplementary file 1J). The effect of G6PDd score on cerebral malaria appeared to be the same
for males (OR = 0.96, p = 1.6x10 3) and females (OR = 0.96, p = 1.4x10 2), whereas its effect on
severe malarial anaemia was more pronounced for males (OR = 1.05, p = 1.8x10 4) than for females
(OR = 1.03, p = 0.12).
Models for balancing selection from opposing effects on cerebral
malaria and severe malarial anaemia
These findings provide an opportunity to re-evaluate the evolutionary factors that cause G6PD defi-
ciency to be maintained in human populations. Several lines of evidence indicate that the G6PD
+202T allele has been under recent positive selection (Tishkoff et al., 2001; Sabeti et al., 2002;
Tripathy and Reddy, 2007) and the main driving force for positive selection is thought to be hetero-
zygote advantage against malaria in females (Bienzle et al., 1972; Luzzatto, 2015). These and other
recent data confirm that female heterozygotes do have an advantage against cerebral malaria, but
raise the question of whether this is a sufficient explanation for current levels of G6PD deficiency,
given that female homozygotes and male hemizygotes have increased risk of severe malarial
anaemia.
To examine this question, we adapted the theoretical model introduced by Levene (Lev-
ene, 1953) to model these different selective forces on the frequency of the G6PD+202T allele
(see Materials and methods). This necessitated a number of simplifying assumptions. First, we
assume that the fitness of this allele is determined only by the effects on severe P. falciparum malaria
described in Table 7, i.e. we do not consider the possible effect of this allele on the risk of other dis-
eases, including those caused by other Plasmodium species and haemolytic anaemia in general.
Table 5. Calculation of the G6PD deficiency (G6PDd) score. The G6PDd score is calculated on the basis of the haplotypes at the 15
WHO-classified SNPs. For each haplotype, the loss of normal G6PD function is determined according to the WHO severity class (0, I,
II, III or IV) of the most severe mutation carried. See Materials and methods for more details. The G6PDd score for each individual is
then the average loss of function across the two haplotypes, where males are treated as homozygous females. For example, the
assigned loss of normal G6PD function for a haplotype where the most severe mutation is the class III mutation G6PD+202T is 65, so
an individual with this haplotype and another with no deficiency mutations will average a G6PDd score of 32.5. Individuals were further
categorized on the basis of their G6PDd score as normal G6PDd (G6PDd score = 0); Low G6PDd (0 < G6PDd score < 25, blue boxes);
Medium G6PDd (25  G6PDd score < 50, yellow boxes); High G6PDd (50  G6PDd score < 85, orange boxes); or Very High
(G6PDd  85, red box). Scores not observed in our study are shown in grey boxes.
G6PDd score
Haplotype 1
Severity class (loss of normal G6PD function)
0 (0) IV (20) III (65) II (95) I (100)
Haplotype 2 Severity class
(Loss of normal G6PD function)
0 (0) 0 10 32.5 47.5 50
IV (20) 10 20 42.5 57.5 60
III (65) 32.5 42.5 65 80 82.5
II (95) 47.5 57.5 80 95 97.5
I (100 50 60 82.5 97.7 100
DOI: 10.7554/eLife.15085.012
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Second, the model requires us to specify the rates of mortality due to severe malaria over the past
few thousand years. Childhood malaria mortality rates of approximately 5% have been observed in
Africa in the recent past (Greenwood et al., 1987), but are likely to have been much higher before
the advent of malaria control and modern medicine. Cerebral malaria currently has a much higher
fatality rate than severe malarial anaemia (in this study, the average case fatality rates were 18% and
5%, respectively), but mortality from severe malarial anaemia is likely to havebeen considerably
higher in the past, before the introduction of blood transfusion. For purposes of illustration, we
assume that childhood mortality due to malaria has historically been in the range of 10–20%, that all
of these deaths were due to cerebral malaria or severe malarial anaemia, and that the mortality rate
of cerebral malaria has been approximately twice that of severe malarial anaemia.
Table 6. G6PD deficiency score categorical model association test results. Counts, odds ratios (ORs), 95% confidence intervals (95%
CI) and P-values are presented for the effect of each category of G6PD deficiency (G6PDd) score, compared to individuals with G6PDd
score = 0, for all severe malaria cases and for the two subtypes cerebral malaria and severe malarial anaemia. P-value shown in bold is
for overall model fit. P-value for the overall model fit. Results are shown for all individuals combined at each site and across all sites.
Results are adjusted for the sickle-cell trait, ethnicity and sex. n.c., not calculated.
Sample
G6PDd score
category
Controls Severe malaria Cerebral malaria Severe malarial anaemia
N (%) N (%) OR (95% CI) P N (%) OR (95% CI) P N (%) OR (95% CI) P
Females 0 3,761
(46.4)
2,299
(42.6)
– – 672 (42.3) -– -– 400 (39.8) -– -–
All (0–25) 2,132
(26.3)
1,626
(30.1)
0.98 (0.9–
1.08)
0.72 495 (31.2) 1.02 (0.89–
1.17)
0.81 306 (30.4) 1.08 (0.9–1.29) 0.41
(25–50) 2,001
(24.7)
1,310
(24.3)
0.88 (0.8–
0.97)
8.59E-
03
377 (23.7) 0.83 (0.71–
0.96)
1.04E-
02
252 (25.1) 1 (0.83–1.21) 0.99
All (50–85) 210 (2.6) 156 (2.9) 1.02 (0.81–
1.28)
0.85 44 (2.8) 0.93 (0.66–
1.31)
0.67 45 (4.5) 1.71 (1.16–
2.53)
6.86E-
03
85 2 (0) 8 (0.1) 7.3 (1.43–
37.24)
0.02 0 (0) n.c n.c. 2 (0.2) 9.72 (1.01–
93.12)
0.05
Overall 8,106 5,399 3.68E-
03
1,588 – 0.06 1,005 – 0.03
Males 0 5,960
(67.9)
4,216
(65.1)
-– -– 1,212
(68.4)
– – 707 (60) – –
All (0–25) 1,572
(17.9)
1,303
(20.1)
1.08 (0.99–
1.19)
0.08 342 (19.3) 1.01 (0.88–
1.16)
0.86 227 (19.3) 1.05 (0.87–
1.25)
0.63
(25–50) 0 (0) 0 (0) n.c n.c. 0 (0) n.c n.c. 0 (0) n.c n.c.
All (50–85) 1,196
(13.6)
923 (14.3) 1.05 (0.95–
1.16)
0.35 214 (12.1) 0.79 (0.67–
0.94)
6.31E-
03
236 (20) 1.44 (1.2–1.74) 1.17E-
04
85 55 (0.6) 30 (0.5) 0.65 (0.4–
1.04)
0.07 3 (0.2) 0.26 (0.08–
0.85)
0.03 9 (0.8) 1.24 (0.58–
2.67)
0.58
Overall 8,783 6,472 -– 0.08 1,771 -– 1.49E-
03
1,179 – 1.97E-
03
All 0 9,721
(57.6)
6,515
(54.9)
– – 1,884
(56.1)
– – 1,107
(50.7)
– –
All (0–25) 3,704
(21.9)
2,929
(24.7)
1.05 (0.99–
1.12)
0.12 837 (24.9) 1.03 (0.93–
1.13)
0.56 533 (24.4) 1.05 (0.93–
1.19)
0.45
(25–50) 2,001
(11.8)
1,310 (11) 0.94 (0.86–
1.03)
0.16 377 (11.2) 0.86 (0.75–
0.99)
0.04 252 (11.5) 0.95 (0.8–1.14) 0.6
(50–85) 1,406 (8.3) 1,079 (9.1) 1.02 (0.93–
1.12)
0.71 258 (7.7) 0.8 (0.69–
0.93)
2.95E-
03
281 (12.9) 1.49 (1.26–
1.76)
2.22E-
06
85 57 (0.3) 38 (0.3) 0.87 (0.55–
1.36)
0.54 3 (0.1) 0.28 (0.09–
0.86)
0.03 11 (0.5) 1.44 (0.66–
3.17)
0.36
All Overall 16,889 11,871 – 0.14 3,359 – 2.29E-
04
2184 – 1.02E-
04
DOI: 10.7554/eLife.15085.013
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We used this simplistic model to investigate the expected change in G6PD+202T allele frequency
over time, from a starting value of 0.01, using different assumptions about the proportion of children
suffering from severe malaria and about the ratio of severe malaria cases due to cerebral malaria
compared to those due to severe malaria anaemia. As shown in Figure 3, as long as the proportion
of cerebral malaria cases remains greater than approximately 27%, the frequency of G6PD+202T
increases over time to an equilibrium value, otherwise it decreases steadily and will be eliminated
(dotted black line on red background). We note that this result is not dependent upon the assumed
proportion of children suffering from severe malaria; changing this will simply change the time taken
to reach equilibrium for any selected ratio of cerebral malaria to severe malarial anaemia cases, not
the equilibrium value itself.
Another way of addressing this question is to consider the number of severe malaria deaths that
can be attributed to, or prevented by, the presence of G6PD+202T allele. At increasing levels of
allele frequency, we would expect the number of cerebral malaria cases to be reduced and the num-
ber of severe malarial anaemia cases to be increased, as shown in Figure 4. For this analysis, we
used the odds ratios observed in this study (Table 7) and assumed a baseline risk of death due to
cerebral malaria of 200 per 10,000 individuals and baseline risks of death due to severe malarial
anaemia of ¼, ½ and 1/3 that of cerebral malaria. When the baseline risk of death due to severe
malarial anaemia is half that of cerebral malaria, the equilibrium frequency of G6PD+202T, where
Figure 2. G6PD deficiency score forest plot. Forest plots showing 95% confidence intervals for the effect of each category of G6PDd score on
all severe malaria and on two sub-phenotypes, cerebral malaria and severe malarial anaemia. Results are shown for all individuals across all sites
combined and are adjusted for the sickle-cell trait, ethnicity and sex. See Table 6 for details and Supplementary files 1H–J for results at all sites for
males, females and all individuals combined.
DOI: 10.7554/eLife.15085.014
The following source data is available for figure 2:
Source data 1. G6PDd score association test results.
DOI: 10.7554/eLife.15085.015
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the number of lives saved equals the number of lives lost, is approximately 28%; whereas at lower
allele frequencies, there are more lives saved than lost, and at higher allele frequencies, there are
more lives lost than saved (solid red and solid blue lines Figure 4). As the baseline risk of death due
to severe malarial anaemia increases relative to that of cerebral malaria, the equilibrium frequency
decreases (solid red and dotted blue lines); and conversely, as the risk of death due to severe malar-
ial anaemia decreases relative to that of cerebral malaria, it increases (solid red and dashed blue
lines). These equilibrium values are consistent with G6PD+202T allele frequencies observed in the
African populations studied here, which ranged from 11% in Cameroon to 28% in Nigeria (excluding
The Gambia where there are other deficiency alleles).
Discussion
In contrast to other malaria resistance loci such as sickle cell trait and blood group O, which show
highly consistent and statistically significant effects across different locations in this large multi-cen-
tre study (Malaria Genomic Epidemiology Network, 2014), the observed associations with G6PD
deficiency are at lower levels of statistical significance and vary between locations
(Supplementary files 1D–J) (Manjurano et al., 2015; Uyoga et al., 2015; Shah et al., 2016). This is
partly because of the genetic complexity of G6PD deficiency, which is affected by multiple allelic var-
iants and has different effects in males and females. Here, we have simplified the problem by esti-
mating each individual’s level of enzyme activity from their genotype, thus enabling an aggregated
analysis to be performed across both sexes and all allelic variants. Another complicating factor is
that severe malaria comprises a variety of different clinical syndromes, of which cerebral malaria and
severe malarial anaemia are the most commonly diagnosed causes of fatal outcome in African chil-
dren. We find significant evidence that increasing levels of G6PD deficiency are associated with
decreasing risk of cerebral malaria, but with increased risk of severe malarial anaemia. The majority
of evidence comes from the large number of individuals carrying the G6PD+202T allele, but it is sup-
ported by evidence from a smaller number of individuals carrying alleles with stronger phenotypic
effects. The net result is that there is no significant association between G6PD deficiency and severe
Table 7. Fitness arrays suggested by observed OR estimates of effect at G6PD+202 on cerebral malaria and severe malarial anaemia.
A1 represents the wild-type allele and A2 the derived allele. In females, odds ratios (ORs) for association with cerebral malaria in
derived homozygotes and heterozygotes compared to wild-type homozygotes are 0.87 and ~1, respectively, suggesting a symmetrical
heterozygous advantage. In males, the OR for association with cerebral malaria in derived, compared to wild-type, hemizygotes is
0.82, suggesting a moderate fitness difference between male genotypes. For severe malarial anaemia, in females, the ORs in derived
homozygotes and heterozygotes, compared to wild-type heterozygotes, are 1.84 and 1, respectively, suggesting selection against
derived homozygotes; in males, the OR in derived hemizygotes, compared to wild-type, is 1.48, suggesting selection against derived
male hemizygotes. The case fatality rate is estimated to be 20% (m = 0.2) for cerebral and 10% (m = 0.1) for severe malarial anaemia.
Genotype
Females Males
A1A1 A1A2 A2A2 A1 A2
w11 w 12 w 22 w 1 w 2
Cerebral malaria selection
Observed OR* 1 0.87 (0.75–1) 1.02 (0.7–1.48) 1 0.82 (0.69–0.97)
Fitness Array† 1–sf
CM 1 1–sf
CM 1–sm
CM 1
Fitness (w) 0.974 1 0.974 0.964 1
Severe malarial anaemia selection
Observed OR* 1 0.97 (0.8–1.17) 1.84 (1.21–2.79) 1 1.48 (1.22–1.8)
Fitness Array‡ 1 1 1–sf
SMA 1 1–sm
SMA
Fitness (w) 1 1 0.954 1 0.968
*Odds ratios are estimated from a genotypic model and are adjusted for sickle-cell trait and ethnicity.
†sf
CM = m(1–OR) = 0.2 (1 0.87) = 0.26. sm
CM = 0.2(1–0.82) = 0.036.
‡sf
SMA = m (1–1/OR) = 0.1 (1–1/1.84) = 0.046; sm
SMA = m(1–1/OR) = 0.1 (1 1/1.48) = 0.032.
DOI: 10.7554/eLife.15085.016
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malaria as a whole. We note that the method used here to calculate G6PDd score is based on a rela-
tively crude classificaiton system of known variants (Yoshida et al., 1971), and there is a need for
additional phenotypic data on the biochemical effects of specific genotypes in order to evaluate the
precise relationship between G6PD enzyme function and the risk of different forms of severe
malaria.
These findings may help to explain apparent inconsistencies between our findings and those of
previous studies, in particular surrounding the question of whether males carrying the G6PD+202T
allele are protected against severe malaria. This is the group of individuals in whom the opposing
effects of G6PD deficiency on cerebral malaria and severe malarial anaemia are most apparent
(Tables 4 and 6) and their overall level of protection against severe malaria might therefore depend
on local circumstances. However, there remain unexplained differences in the patterns of association
that we have observed in different locations (Supplementary files 1G–I) and whilst these might be
due to the small sample size of local analyses, it is possible that they reflect true biological differen-
ces. Severe childhood anaemia in the tropics is often the result of a combination of factors that
include malaria, G6PD deficiency, hookworm, micronutrient deficiency, haemoglobinopathies and
other infectious diseases (Calis et al., 2008; van Hensbroek et al., 2011; Silverberg, 2012;
Kassebaum et al., 2014). Further studies are needed to examine the malaria-protective effects of
G6PD deficiency under different environmental conditions, and in particular how these affects may
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Figure 3. Allele frequency of G6PD+202T. Change in the allele frequency of G6PD+202T under the adapted Levene model. We assume an initial
frequency of 0.01 in both males and females and that the change in allele frequency depends only on genotype fitness as a consequence of relative
exposure to three selective forces: cerebral malaria, severe malarial anaemia and no selection (see Materials and methods). Here we have assumed that,
in each generation, 50% of children suffer from severe malaria and show results for different ratios of cerebral malaria to severe malarial anaemia cases,
as indicated for each coloured polygon. Within each of these polygons, the solid black lines shows the allele frequencies when thefatality rate of
cerebral malaria (severe malarial anaemia) is 20% (10%); the lower bound to 15% (8%); and the upper bound to 25% (12%).
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be influenced by other epidemiological variables that act together to cause anaemia in African
children.
At first sight, these findings appear to challenge the widely accepted hypothesis that G6PD defi-
ciency has evolved in human populations as a result of balancing selection due to malaria (Alli-
son, 1960). They raise the question of how much evolutionary benefit is required to counterbalance
the deleterious effects of G6PD deficiency. A small minority of carriers of G6PD deficiency have
severe mutations that cause congenital haemolytic anaemia (Cappellini and Fiorelli, 2008). The
majority are generally asymptomatic apart from an increased risk of neonatal jaundice, unless an
event occurs to precipitate an acute episode of haemolytic anaemia (Beutler, 1994, 2008;
Valaes, 1994; Kaplan and Hammerman, 2010). Haemolysis-precipitating events include certain
drugs, dietary factors (e.g. fava beans) and infectious disease. The antimalarial drug primaquine,
which is of great practical importance for the treatment and elimination of P. vivax malaria, can pre-
cipitate severe and sometimes fatal haemolytic anaemia in G6PD-deficient individuals (Chu and
White, 2016).
Here we consider a different formulation of the balancing-selection hypothesis, in which the main
evolutionary benefit of G6PD deficiency is decreased risk of cerebral malaria, and its main evolution-
ary disadvantage is increased risk of severe malarial anaemia. We modeled this evolutionary sce-
nario, assuming that childhood mortality resulting from severe malaria has historically been in the
range of 10–20%, that all of these deaths were due to cerebral malaria or severe malarial anaemia,
and that the mortality rate of cerebral malaria has been approximately twice that of severe malarial
anaemia. In this model, G6PD deficiency was positively selected and rose to an equilibrium value as
G6PD+202T allele frequency
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Figure 4. Deaths prevented or caused attributable to the genetic effects at G6PD+202. The solid red line shows the number of deaths due to cerebral
malaria that are prevented by the presence of G6PD+202T, assuming a baseline risk of death due to cerebral malaria of 200/10,000 individuals. The
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the frequency of G6PD+202T is zero. Results are shown as the allele frequency of G6PD+202T increases. Relative risks of disease are estimated by odds
ratios observed in this study.
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long as >27% of the severe malaria cases were due to cerebral malaria. We also took an epidemio-
logical approach to this question, by considering the number of severe malaria cases that can be
attributed to, or prevented by, the presence of the G6PD+202T allele. If we assume a case fatality
rate of 20% for cerebral malaria and 10% for severe malarial anaemia in the absence of treatment
then, based on the odds ratios observed in this study, the epidemiological equilibrium state – where
the number of lives saved equals the number of lives lost – would be achieved at a G6PD+202T
allele frequency of 28%. This is consistent with the 18% median allele frequency that we observe in
African populations where G6PD+202T is the only major deficiency allele.
The evolutionary and epidemiological models presented here are simplistic; for example, they do
not consider the potential impact of spatial and temporal heterogeneity (Saunders et al., 2002) and
they make very approximate assumptions about past prevalence and mortality rates. These models
ignore other potential costs and benefits of G6PD deficiency, such as mortality due to G6PD-
induced haemolytic anaemia that is unrelated to malaria or infant mortality due to G6PD-associated
neonatal jaundice, and the possible protective effects of G6PD deficiency against infectious diseases
other than P. falciparum malaria. Of particular interest for future investigation is the evolutionary sig-
nificance of the protective effect of G6PD deficiency against P. vivax (Louicharoen et al., 2009;
Leslie et al., 2010), a parasite species which appears to have played an important historical role in
human evolutionary selection, as evidenced by the selective sweep of the Duffy-negative blood
group that confers resistance to P. vivax across sub-Saharan Africa (Livingstone, 1984). With these
caveats, the present findings indicate the need for a new formulation of the balancing-selection
hypothesis, in which G6PD polymorphism is maintained in human populations, at least in part, by an
evolutionary trade-off between different adverse outcomes of P. falciparum infection.
Materials and methods
Samples and phenotypes
Cases and controls were recruited from 12 MalariaGEN study sites (Supplementary file 1A). Cases
of severe malaria were recruited on admission to hospital, usually as part of a larger program of clini-
cal research on malaria, designed and led by local investigators. A population control group, with
similar ethnic composition to the cases, was recruited at each of the study sites: cord blood samples
were used as population controls at several study sites. The cases and controls included children
from 213 different ethnic groups of which 41 comprised at least 5% of individuals at a study site;
these included Mandinka, Jola, Wollof, Fula (Gambia); Bambara, Malinke, Peulh, Sarakole (Mali);
Mossi (Burkina Faso); Akan, Frarra, Nankana, Kasem (Ghana); Yoruba (Nigeria); Bantu, Semi-Bantu
(Cameroon); Chonyi, Giriama, Kauma (Kenya); Mzigua, Wasambaa, Wabondei (Tanzania); Chewa
(Malawi); Madang, Sepik (Papua New Guinea); Kinh (Viet Nam). For purposes of analysis, we classi-
fied ethnic groups with very small sample size (less than 5% of individuals at any study site) as
‘other’. Details of study design at individual sites, collection of clinical and genotype data as well as
local epidemiological conditions including malaria endemicity are described in detail elsewhere
(Malaria Genomic Epidemiology Network, 2008, 2014) and information about each of the partner
studies can be found the Malaria Genomic Epidemiology Network (MalariaGEN) website (see URLs).
The normalised data from each study site were combined to ascertain phenotypes in a standar-
dised manner across the entire data set. A case of severe malaria was defined as an individual admit-
ted to a hospital or clinic with P. falciparum parasites in the blood film and with clinical features of
severe malaria as defined by WHO criteria (World Health Organisation, 2000, 2010). Severe
malaria comprises a number of overlapping syndromes; the most commonly reported being cerebral
malaria and severe malarial anaemia. In keeping with standard criteria, cerebral malaria is defined
here as a case of severe malaria with Blantyre Coma Score of <3 for a child, or a Glasgow Coma
Score of <9 for an adult. Severe malarial anaemia is defined here as a case of severe malaria with a
hemoglobin level of <5g/dl or a hematocrit level of <15%. In this report, we do not attempt to clas-
sify other severe malaria syndromes such as respiratory distress, which are more complicated to stan-
dardise between study sites. A total of 38,926 individual records comprising 16,433 cases of severe
malaria and 22,492 controls were obtained from across the 12 study sites (Supplementary file 1A).
Data were missing for gender in 4% of records and for ethnic group in 2% of records. 33,138 sam-
ples were retained for genotyping (Supplementary file 1B).
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Ethics
All studies were collected under the approval of the appropriate ethics committees, and all partici-
pants gave informed consent. Please refer to Supplementary file 1A and the MalariaGEN website
(see URLs) for further details.
Genotyping
As the starting point for analysis of genetic variation at the G6PD locus in these samples, we identi-
fied 251 known variants in a survey of the literature and polymorphism databases and an additional
57 variants using targeted Sanger sequencing of the G6PD locus in 288 individuals comprising 48
randomly selected from Burkina Faso, Cameroon, Kenya, Nigeria, Papua New Guinea and Vietnam.
A set of four Sequenom multiplexes was designed for 135 of these SNPs with priority assigned
according to proximity to the G6PD locus, evidence of a functional role and feasibility of assay
design (Supplementary files 2A,B). These assays were first tested on a set of 90 HapMap DNA sam-
ples each from the CEU and YRI populations. Failing assays were removed and a new set of multi-
plexes (W1186-W1189) was re-configured containing 107 assays. They were used to genotype a set
100 individuals randomly selected from each of the populations in the study plus the 288 sequenced
samples (Supplementary file 2C). This provided information on assay performance and population
allele frequencies and was used to reduce the number of SNPs carried forward into the main study
for reasons of economy and scale: 59 SNPs were selected for a final set of three multiplexes based
on location in the exons of G6PD, the introns of G6PD, the first 5 kb of the 5’ sequence of G6PD,
and the frequency in the screen populations. Nine additional SNPs were subsequently added that
were shown to be in long-range-haplotypes with G6PD (Sabeti et al., 2002) (Supplementary file
2A). The reduction from four multiplexes into three multiplexes using existing working assay designs
was managed using the Sequenom AssayDesigner software and replexing feature. The final SNPs
set comprised 3 multiplexes containing 68 SNPs, of which 54 are assigned to G6PD
(Supplementary file 2D). The two G6PD SNPs (rs1050828 and rs1050829) typed in our previous
study (Malaria Genomic Epidemiology Network, 2014) were also included, resulting in 70 SNPs
available for analysis. They ranged from rs763737 at 153,278,307 bp to rs60030796 at 153,836,171
bp (where coordinates are referenced to GRCh37, dbSNP137 and Ensembl build 84). All retained
samples were genotyped at these 70 SNPS. Genotype data for these samples were also available
within a set of SNPs with prior evidence of association with severe malaria phenotypes, including the
sickle hemoglobin (HbS) variant, rs334. The above SNPs were genotyped using whole-genome
amplified DNA on the Sequenom iPLEX Mass-Array platform (Agena Biosciences, Hamburg, Ger-
many) as described elsewhere (Malaria Genomic Epidemiology Network, 2014)
Following genotyping of the final set of 70 SNPs, five SNPs were removed because of missing
data in more than 30% of samples. 2,918 individuals were removed because of missing data in more
than 20% of the remaining 65 SNPs (Supplementary file 1B) and 1,460 individuals were removed
because of missing severe malaria classification, leaving 11,871 severe malaria cases and 16,889 con-
trols (Table 1), and 65 SNPs (Supplementary file 1C), for further analysis.
Phasing
The X chromosome is paired (diploid) in females and haploid in males. Male haplotypes are there-
fore phase-known but female haplotypes require phasing. We phased female haplotypes using
Shapeit2 (Delaneau et al., 2012). In order to verify the accuracy of phasing, half of the male phase-
known haplotypes (8,030 of 16,060) were randomly paired to produce 4,015 phase-known (‘pseudo-
female’) samples, and phasing was repeated for a simulated dataset comprising the remaining 8,030
males, all the females and the 4,015 phase-known samples. The resulting phased haplotypes in the
4,015 pseudo-female samples were compared to the phase-known haplotypes.
The phased and phase-known haplotypes from the pseudo female samples were then compared
by recording the mismatches at heterozygous loci. For each sample, each phased haplotype was
assumed to represent phasing for the phase-known haplotype with the fewest mismatches. In our
data, 71% of the haplotypes had less than 10% of the haplotype incorrectly phased across the 65
SNPS. Across the 15 SNPs with a WHO classified G6PD deficiency classification, 83% of haplotypes
had less than 10% of the haplotype incorrectly phased. Phasing of the original data is expected to
have greater accuracy than the phasing of the simulated data because the simulated data effectively
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have 8,030 fewer phase-known samples and 4,105 more phase-unknown samples than the original
data.
G6PD deficiency score
The WHO classification system divides G6PD deficiency variants into four classes of
severity (Yoshida et al., 1971):
I. Severe mutations; total loss of normal G6PD function
II. Intermediate; >90% loss of normal G6PD function
III. Mild; 40–90% loss of normal G6PD function
IV. Asymptomatic; 0–40% of normal G6PD function
Using phased data at the 15 SNPs with a WHO classification, a quantitative measure of G6PD
deficiency for each individual was calculated. Each phased haplotype of 15 SNPs was assigned to
one of the four classes of deficiency according to the most severe deficiency variant carried. The loss
of normal G6PD function for the haplotype was then assigned according to that class. The WHO
classification specifies a range of values for each class of deficiency and here we used the median of
the range:
. Haplotypes carrying no mutation = 0.
. Haplotypes carrying a class I mutation = 100
. Haplotypes carrying a class II mutation = 95
. Haplotypes carrying a class III mutation = 65
. Haplotypes carrying a class IV mutation = 20
The G6PDd score for each individual was then calculated as the average of the assigned loss of
function over each of their two haplotypes, where males are treated as homozygous females
(Table 5). Observed G6PDd score ranged from 0 to 95. For example, individuals heterozygous for
WHO class III variant G6PD+202T and no other mutations scored 65; female homozygotes and male
hemizygotes for G6PD+202T scored 80.
Individuals were further categorized on the basis of their G6PDd score as Normal (G6PDd
score = 0); Low (0 < G6PDd score <25, blue boxes in Table 5); Medium (25  G6PDd score <50, yel-
low boxes in Table 5); High (50  G6PDd score <85, orange boxes in Table 5); or Very high (G6PDd
score 85, red boxes in Table 5).
In our sample of 28,760 individuals included in the final analysis, there were only six individuals
(<0.02%) who carried more than one mutation on the same phased chromosome, making them
potentially vulnerable to an incorrectly calculated G6PDd score in the event of incorrect phasing.
These six individuals comprised three females from Gambia, who carried two class II mutations, and
two females from Ghana (Kumasi) and one from Burkina Faso, who carried two class III mutations.
Statistical association analysis
We drew on both classical and Bayesian statistical approaches to assess evidence for association. All
statistical analyses were primarily written and performed using the statistical software environment R
(see URLs).
Standard fixed effects analyses
In primary analyses, standard fixed effects logistic regression methods were used for tests of associa-
tion with severe malaria and sub-types at each SNP under additive, dominant, recessive and hetero-
zygous models. Analyses were run separately at each site and then at all sites combined, both for
males and females separately and in combination. When examining all sites combined, sites where a
SNP was monomorphic were excluded from the analysis. Results were adjusted for sickle hemoglo-
bin (HbS), gender and ethnicity. Ethnicity was not shared across any sites. Here, we report on analy-
ses looking for evidence of association with severe malaria and with the two sub-types of fatal
severe malaria that are most commonly diagnosed in African children, namely cerebral malaria and
severe malarial anaemia. For reasons of sample size, we did not conduct a detailed analysis of other
sub-types of severe malaria, or of those individuals who had both cerebral malaria and severe malar-
ial anaemia, but summary statistics are available in Figure 1—source data 1 and 2. Males were
treated as homozygous females and so for analysis of males only, dominant, recessive and additive
models are equivalent and the heterozygous model is redundant; in this case, we refer to the model
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as hemizygote and note that the odds ratios (OR) correspond to the change in odds of disease for
males hemizygous for the derived allele compared to males hemizygous for the ancestral allele. For
combined analyses of males and females at X-chromosome SNPS, robust estimates of variance were
used to account for the unequal variance (Clayton, 2008) and all models are then appropriate. Sig-
nificance, ORs and 95% confidence intervals were derived from Wald tests applied to regression
coefficients. Results are presented with respect to the association between the derived (non-ances-
tral allele) and the severe malaria phenotype in question. A P-value for heterogeneity of the effect of
each SNP between severe malaria sub-phenotypes cerebral malaria and severe malarial anaemia was
calculated in a logistic regression framework by comparing cerebral-malaria-only cases against
severe-malarial-anaemia-only cases. Standard fixed effects logistic regression methods were used to
test associations with the G6PDd score with and without adjustment for an additive effect at G6PD
+202. To calculate the G6PDd score, the data was phased using SHAPEIT2 (Delaneau et al., 2013).
See Phasing for more details.
Adjustment for additional risk factors
To investigate the impact of age on risk of severe malaria, we used logistic regression to estimate
odds ratios for the risk of cerebral malaria and severe malarial anaemia in cases of various age strata
compared to controls. Figure 1—figure supplement 2 shows forest plots for the effects of G6PD
+202T and the G6PDd score on cerebral malaria and severe malarial anaemia in cases in yearly inter-
vals from age 0–6 years and greater than six years, compared to controls. We note that our study is
based on a multi-centre collection of severe malaria cases and population controls and was not
designed to enable a rigorous study of the effects of age as a possible factor. For this analysis, we
have grouped all controls together, assuming that the allele frequency observed in controls is repre-
sentative of the population allele frequency and that it does not change with age.
To investigate the influence of known genetic factors on association with severe malaria at the
G6PD gene, we re-analyzed the association between G6PD+202 and the G6PDd score with adjust-
ment for ABO (rs8176719), ATP2B4 (rs10900585), FREM3/GYPE (rs149914432) and HbC
(rs33930165). Genotype data for these SNPs for individuals in our study were available from our pre-
vious study (Malaria Genomic Epidemiology Network, 2014). Figure 1—figure supplement 3
shows ORs and 95% confidence intervals for each test of association (only shown for tests with P-
value < 0.05) with and without adjustment for these additional factors.
Genetic heterogeneity
To allow for possible differences in genetic effects on the two severe malaria sub-phenotypes —
cerebral malaria and severe malarial anaemia — within and across sites, we compared different mod-
els of association in a Bayesian statistical framework as described in detail elsewhere
(Malaria Genomic Epidemiology Network, 2014). In brief, we calculated Approximate Bayes Fac-
tors (ABF) for nine models of association, allowing for all combinations of fixed and independent
effects on phenotypes within and across sites. For each SNP, we assumed that the log odds ratio of
association was normally distributed with a mean of zero and standard deviation of 0.4. To model
fixed, independent or correlated effects both within and across sites, we set correlation parameters
between sub-phenotypes to 1, 0.1 and 0.96, respectively. Multinomial regression was used to make
independent maximum likelihood estimates of the effect of each SNP on cerebral malaria and severe
malarial anaemia, using cases with either cerebral malaria only or with severe malarial anaemia only.
Estimates were adjusted for sex, ethnicity and sickle-cell trait (rs334) and were made separately for
males and females, with males being treated as homozygous females; meta-analysis was used to
make combined estimates for males and females. The posterior probability of each model was then
calculated as the relative size of its ABF compared to that of all other models considered and evi-
dence for heterogeneity was assessed by comparing the posterior probabilities of the selected
models.
Theoretical model for a balanced polymorphism
In order to examine how the different effects observed in males and females in cerebral malaria and
severe malarial anaemia could lead to a balanced polymorphism at G6PD+202, we have adapted
the theoretical model introduced by Levene (Levene, 1953) to model the allele frequency over time
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of an X-linked locus allowing for multiple selective forces. In this simple model, it is assumed that the
population mates at random and that the progeny then settle at random into one of multiple mutu-
ally exclusive ‘niches’. There is then differential mortality in each niche before random mating across
all niches produces the next generation. Here, we are adapting Levene’s concept of a ‘niche’ to rep-
resent a proportion of the population suffering from a particular severe malaria sub-phenotype, and
then modelling the allele frequency as a combination of the selective effects from multiple niches
over time and space.
We now derive the conditions for a polymorphism as a result of a different selection regime in
each niche at an X-linked locus. Consider an X-linked biallelic locus with alleles a and A. For the ith
niche: let pm,i and pf,i be the frequencies of a in males and females; qm,i and qf,i the corresponding
frequencies for A; waa.i, waA.i and wAA.i the fitness of females carrying aa, aA and AA
genotypes, respectively; and wa and wA the fitness of males carrying a and A alleles. Recursion equa-
tions give the next generation’s male and female allele frequencies as a function of the current gen-
eration’s (Haldane and Jayakar, 1964):
q0m;i ¼
qfwA;i
pfwa;iþ qfwA;i
(1)
q0f ;i ¼
1
2

pf qmþ qf pm
  
waA;iþ 2qf qmwAA;i
pf pmwaa;iþ pf qmþ qf pm
  
waA;iþ qf qmwAA;i
(2)
Suppose in general that there are n niches, and that ci is the proportion of individuals from niche
i, then the mean frequency of the next generation’s male and female alleles is
q0m ¼
Xn
i¼1
ciq
0
m;i (3)
q0f ¼
Xn
i¼1
ciq
0
f ;i (4)
If there are equal numbers of males and females in the population, then two-thirds of the alleles
are in the females and one-third are in males for this X-linked locus and the mean allele frequency in
the next generation will be
q0 ¼
2
3
q0f þ
1
3
q0m (5)
When allele A is rare, qm and qf are close to zero, and Equation 3 and Equation 4 approximate
to
q0m ¼ qf
Xn
i¼1
ciwA;i
wa;i
(6)
q0f ¼
qmþ qf
  
2
Xn
i¼1
ciwaA;i
waa;i
(7)
The A allele can invade when the larger eigenvalue of the Jacobian of this system of equations is
greater than one (Hartl and Clark, 1989; Patten and Haig, 2009): the approximate invasion condi-
tion for allele A is:
1þ
Xn
i¼1
ci
wa;i
wA;i
  Xn
i¼1
ci
waA;i
2wAA;i
 
>1 (8)
Similarly, it can be shown that the approximate invasion condition for allele a is:
1þ
Xn
i¼1
ci
wA;i
wa;i
  Xn
i¼1
ci
waA;i
2waa;i
 
>1 (9)
A balanced polymorphism is possible for an X-linked allele under spatial variation when Equa-
tion 8 and Equation 9 are simultaneously satisfied.
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In our application, we have three ‘niches’, or equivalently, a combination of three selective forces:
cerebral malaria, severe malarial anaemia and no malaria. Essentially, the proportion of individuals in
each niche is a proxy for the proportion of children suffering from the corresponding severe malaria
subphenotype, or not suffering from severe malaria. In the absence of severe malaria, we assume
that all selection coefficients are zero, otherwise, we estimate the selection coefficients for the differ-
ent genotypes from our estimated ORs (Table 7). If the OR indicates a protective effect (OR <1),
then the estimated selection coefficient against disease for that genotype can be estimated as s = m
(1–OR), where m is the case fatality rate (Hill, 1991; Hedrick, 2004). Hedrick (Hedrick, 2011) sug-
gests a value of m = 0.1 for severe malaria to take into account mortality over many generations
when malaria was endemic as well as the cumulative mortality of individuals with malaria prior to
reproduction. As reports estimate that cerebral malaria has a mortality rate that is twice that of
severe malarial anaemia (Thuma et al., 2011), we use m = 0.1 for severe malarial anaemia and
m = 0.2 for cerebral malaria. In African studies of children aged 0–5 years (Severe malaria, 2014), it
has been estimated that the current prevalence of coma and anaemia in severe P. falciparum malaria
is 38% and 52%, respectively, indicating a ratio of 42:58 of cerebral malaria to severe malarial anae-
mia cases. The change in the frequency of G6PD+202T over time for this ratio and others, assuming
an initial frequency of 0.01 and that 50% of children suffer from severe malaria, is shown in Figure 3.
Deaths prevented or caused attributable to genetic effects at G6PD
+202
The risk ratio (RR), which can be estimated by the odds ratio, is a measure of the strength of associa-
tion between one or more risk factors (here the genotypes) and an outcome (here severe malaria). In
order to provide information about the importance of the risk factors at the population level, the fre-
quency of the risk factors must be taken into consideration. Let D be an indicator of disease (D = 1 if
affected and D = 0 otherwise). The total risk of disease is
P D¼ 1ð Þ ¼ f
X
g
RRgP gð Þ (10)
where g denotes the set of risk factors, f the baseline risk of disease and RRg the relative risk of risk
factor g compared to the baseline.
Consider a genotype g at an X-linked disease susceptibility locus with alleles a and A, where allele
A is considered to be the risk allele. Let pA denote the frequency of allele A, assumed to be the
same in both males and females, and fg= Pr(D = 1|g) the risk of disease in individuals carrying geno-
type g. Furthermore, let RRg = fg/faa denote the relative risk in females carrying genotypes g = aA,
AA, respectively, compared to those carrying the baseline genotype aa and, similarly, let RRA = fA/fa
denote the relative risk in males carrying genotype A compared to those carrying the baseline geno-
type a. Assuming Hardy-Weinberg equilibrium and applying (Equation 10) above
P D¼ 1jfemaleð Þ ¼ faa 1  pAð Þ
2þ 2RRaApA 1  pAð Þþ RRAAp
2
A
 
(11)
P D¼ 1jmaleð Þ ¼ fa 1  pAð Þþ RRApAð Þ (12)
Using (Equations 11 and 12) and assuming equal numbers of males and females, a common
baseline risk of disease, f = faa = fa, and common case fatality rate (m) in both males and females, it
is then straightforward to show that the expected number of deaths (ND) due to disease in a popula-
tion of size N is
ND ¼
1
2
1  pAð Þ 2  pAð Þþ 2RRaApA 1  pAð Þþ RRAAp
2
Aþ RRApA
  
 N f m (13)
Note that Nfm is the expected number of deaths due to disease in a population of size N when
the frequency of the risk allale A is zero (pA = 0) and is referred to as the baseline number of deaths
per population size N, or baseline risk. Number of deaths for a given frequency that are attributable
to allele A is then calculated as ND – Nfm. When allele A is protective, ND – Nfm <0, indicating
deaths prevented that are attributable to allele A; when allele A is risk, ND – Nfm > 0, indicating
deaths caused that are attributable to allele A.
Assuming RRs of 1.84 (1.48) for risk of severe malarial anaemia in females homozygous (males
hemizygous) for G6PD+202T compared to wild-type homozygotes (hemizygotes) (per OR estimates
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in Table 7) and null risks otherwise, we calculate ND for various values of Nfm as the allele frequency
pA varies. We also calculate similar values for cerebral malaria assuming RRs of 0.87 (0.82) for risk of
cerebral malaria in females heterozygous (males hemizygous) for G6PD+202T compared to wild-
type homozygotes (hemizygotes) (per OR estimates in Table 7) and null risks otherwise. Figure 4
shows |ND – Nfm| as a function of pA for selected baseline risks.
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